Huafu Securities released a research report on April 21 stating that it gave Antu Biotech (603658.SH) a purchase rating, and the target price was 65.48 yuan. The main reasons for the rating include: 1) the company released the 2023 annual report and the 2024 quarterly report, with impressive Q1 profit growth; 2) steady endogenous business growth, improving the business structure to raise profit levels; 3) steady immunological testing revenue and an overall marginal improvement in the gross margin of reagent products; 4) the IVD multi-platform layout is progressing smoothly, and overseas expansion is growing at a high rate, and I am optimistic about the potential for subsequent acceleration. (Mainichi Keizai Shimbun)
华福证券4月21日发布研报称，给予安图生物（603658.SH）买入评级，目标价格为65.48元。评级理由主要包括：1）公司发布2023年年度报告及2024一季报，Q1利润增长亮眼；2）内生业务增速稳健，业务结构改善提升利润水平；3）免疫检测收入稳健，试剂产品毛利率整体边际改善；4）IVD多平台布局进展顺利，海外拓展高增长，看好后续提速潜力。（每日经济新闻）
Huafu Securities released a research report on April 21 stating that it gave Antu Biotech (603658.SH) a purchase rating, and the target price was 65.48 yuan. The main reasons for the rating include: 1) the company released the 2023 annual report and the 2
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.